Skip to main content

PE-22-28 vs Dulaglutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

PE-22-28

PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.

Full details →

Dulaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.

Full details →

Side-by-Side Comparison

AspectPE-22-28Dulaglutide
MechanismDerived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways.GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression.
Typical DosageResearch protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established.Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response.
AdministrationIntranasal administration preferred for CNS delivery. Research compound with limited human use data.Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens.
Side EffectsVery limited human data. Primarily studied in animal models for safety and efficacy.Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration.
Best For

Key Differences

Unique to PE-22-28:

Unique to Dulaglutide:

Detailed Analysis

Dulaglutide and PE-22-28 are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Dulaglutide for Fat Loss. Choose PE-22-28 for Cognitive Performance, Anti-Aging & Longevity.

Ready to Learn More?